PHAT NASDAQ
Phathom Pharmaceuticals, Inc.
1W: -5.2%
1M: -25.3%
3M: -39.2%
YTD: -56.0%
1Y: -43.7%
3Y: -32.9%
5Y: -78.3%
$6.92
-0.16 (-2.26%)
Weekly Expected Move ±9.0%
$6
$6
$7
$8
$8
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (48)
Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD
Squarepoint Ops LLC Lowers Stock Position in Phathom Pharmaceuticals, Inc. $PHAT
Phathom Pharmaceuticals (NASDAQ:PHAT) Reaches New 12-Month Low – Time to Sell?
Bank of New York Mellon Corp Purchases Shares of 152,313 Phathom Pharmaceuticals, Inc. $PHAT
Phathom Pharmaceuticals, Inc. (PHAT) Reports Break-Even Earnings for Q2
Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives $24.50 Average Target Price from Analysts
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
Phathom Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
Phathom (PHAT) Q1 2026 Earnings Transcript
Phathom Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates
Phathom Pharmaceuticals gives mixed Q1 results
Earnings Scheduled For April 30, 2026
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Phathom Pharmaceuticals Q1 2026 Earnings Preview
12 Health Care Stocks Moving In Wednesday's After-Market Session
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Rating of “Moderate Buy” from Analysts
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up on Analyst Upgrade
Phathom upgraded at Barclays following pullback, Voquezna optimism
This Argan Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday
Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study
ImmunityBio Rises on China Nod to Bladder Cancer Combo Therapy
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives $22.25 Consensus PT from Brokerages
Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why
Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM
Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Up 14.3% Following Earnings Beat
Phathom (PHAT) Q4 2025 Earnings Call Transcript
Phathom outlines $320M–$345M 2026 revenue guidance as company targets operating profitability
Phathom Pharmaceuticals, Inc. (PHAT) Q4 2025 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Beats Revenue Estimates
Phathom Pharmaceuticals Non-GAAP EPS of -$0.08 beats by $0.11, revenue of $57.6M beats by $0.16M
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance
Here are the major earnings before the open Thursday
Phathom Pharmaceuticals Q4 2025 Earnings Preview
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026
Phathom Pharmaceuticals Pivots to GI Focus, Targets 2H 2026 Profitability, CEO Says at Guggenheim Summit
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Average Recommendation of “Moderate Buy” by Analysts
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth